BGLCBioNexus Gene Lab Corp.
Is BioNexus Gene Lab struggling financially?
Yes, by its own account. BioNexus Gene Lab told the SEC on 15 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.
Going concern disclosed May 2026
15/100
Critical
- Sector
- Biotech/Pharma
- Market cap
- $4.7M
- Source filing
- 10-Q 15 May 2026
- Balance sheet
- 30 Jun 2026
Cash runway
-
4months
If the burn speeds up
Empty by Oct 2026
-
7months
If it eases off
Empty by Jan 2027
Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.
Out of cashTwo years or more
The runway math
Cash and short-term investments
$1.2M
÷
Cash burned over the last 12 months
$2.6M
What BioNexus Gene Lab told the SEC
…outflows from operating activities of $ 147,671 and as of March 31, 2026, the Company incurred an accumulated deficit of $ 6,970,802 . These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. The financial statements do not include any adjustments that might be necessary if the Company is unable to…
BioNexus Gene Lab Corp., Form 10-Q, filed 15 May 2026.
Read the filing on SEC.govWhat this means
- Not a bankruptcy filing, and not a prediction.
- It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
- The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.
What else the numbers show
- 34.5% share-count increase The company issued stock. Each share now owns 25.7% less of the business than a year ago, before any change in the price.
- Cash burn is narrowing It is spending 48% less cash per year than it was, so the runway above is lengthening rather than shortening.
Other Biotech/Pharma companies that filed the doubt
- SSII SS Innovations International $718.4M
- ADVB Advanced Biomed $13.4M
- AIM Aim Immunotech $7.9M
- PTN Palatin Technologies $17.2M
- VSTM Verastem $624.0M
- CRVO CervoMed $39.6M